CFO
AVDL

CVA Family Office’s Avadel Pharmaceuticals AVDL Stock Holding History

CVA Family Office’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95
Closed -$998 – 1400
2024
Q4 		$998 Buy
+95
New +$1.15K ﹤0.01% 1090

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CVA Family Office's AVDL Position: Q1 2025 in Review

CVA Family Office sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 95 shares — an estimated $998 sold.

CVA Family Office first reported a position in AVDL in Q4 2024 and held it in 1 quarter. The position peaked at $998 in Q4 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • CVA Family Office reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • CVA Family Office sold 95 Avadel Pharmaceuticals shares in Q1 2025, an estimated $998.
  • CVA Family Office first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • CVA Family Office's Avadel Pharmaceuticals position peaked at $998 in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on CVA Family Office's 13F filing for Q1 2025, filed 16 Apr 2025.